Skip to main content
. 2022 Apr 5;8(1):e12292. doi: 10.1002/trc2.12292

FIGURE 2.

FIGURE 2

Primary endpoint: Mean score change analysis. The mean and 95% confidence interval were delineated for each follow‐up time. The high‐dose group's ADAS‐Cog trend had a peak reduction at the 8th week but gradually increased at the 16th and 24th weeks. The low‐dose group showed a constant diminishable trend but with an insignificant change. For details of other neuropsychiatric tests, see Table S2. All adjusted Pattained from the linear mixed model after adjusting for age, sex, education years, AChEI use status, follow‐up time, and baseline cognitive score of each test. *Adjusted P of the group = .057. †Statistically significant adjusted P of the group = .026. ‡Adjusted P of the group = .252. §Statistically significant adjusted P of the group = .049. AChEIs, acetylcholinesterase inhibitors; ADAS‐Cog, Alzheimer's Disease Assessment Scale–Cognitive Subscale, 11‐task version; TMSE, Thai Mental State Examination